Antibiotic use and Influencing Factors Among Hospitalized Patients with COVID-19: A Multicenter Point-Prevalence Study from Turkey

Background: Broad-spectrum empirical antimicrobials are frequently prescribed for patients with coronavirus disease 2019 (COVID-19) despite the lack of evidence for bacterial coinfection. Aims: We aimed to cross-sectionally determine the frequency of antibiotics use, type of antibiotics prescribed, and the factors influencing antibiotics use in hospitalized patients with COVID-19 confirmed by polymerase chain reaction. Study Design: The study was a national, multicenter, retrospective, and single-day point prevalence study. Methods: This was a national, multicenter, retrospective, and single- day point-prevalence study, conducted in the 24-h period between 00:00 and 24:00 on November 18, 2020, during the start of the second COVID-19 peak in Turkey. Results: A total of 1500 patients hospitalized with a diagnosis of

PDF

___

1. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020;71:2459-68. [CrossRef]
2. Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013;7 Suppl 2:105-13. [CrossRef]
3. Beovic B, Dousak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: A “snapshot” Infectious Diseases International Research Initiative (ID- IRI) survey. J Antimicrob Chemother. 2020;75:3386-90. [CrossRef]
4. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27:9-11. [CrossRef]
5. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266-75. [CrossRef]
6. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-9. [CrossRef]
7. Turkey Coronavirus: 3,745,657 Cases and 33,454 Deaths - Worldometer n.d. https:// www.worldometers.info/coronavirus/country/turkey/ (accessed April 10, 2021).
8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19- Final Report. N Engl J Med. 2020;383:1813-26. [CrossRef]
9. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83-8. [CrossRef]
10. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395-9. [CrossRef]
11. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during covid-19 surge in New York City. J Clin Microbiol. 2020;58. [CrossRef]
12. Wang L, Amin AK, Khanna P, et al. An observational cohort study of bacterial co- infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. J Antimicrob Chemother. 2021;76:796- 803. [CrossRef]
13. Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis. 2021;53:102-10. [CrossRef]
14. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy R, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol. 2021;93:1489-95. [CrossRef]
15. Ghazi IM, Nicolau DP, Nailor MD, Aslanzadeh J, Ross JW, Kuti JL. Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. Infect Control Hosp Epidemiol. 2016;37:583- 9. [CrossRef]
16. Bartley PS, Deshpande A, Yu PC, et al. Bacterial coinfection in influenza pneumonia: Rates, pathogens, and outcomes. Infect Control Hosp Epidemiol. 2022;43:212-7. [CrossRef]
17. Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. J Infect. 2020;81:e55. [CrossRef]
18. Aytaç ERDEM H, Korkmaz Ekren P, Çağlayan D, et al. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turk J Med Sci. 2021;51:912-20. [CrossRef]
19. Calderón-Parra J, Muiño-Miguez A, Bendala-Estrada AD, et al. Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. Plos One. 2021;16:e0251340. [CrossRef]
20. Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020;9:353. [CrossRef]
21. Van Laethem J, Wuyts S, Van Laere S, et al. Antibiotic prescriptions in the context of suspected bacterial respiratory tract superinfections in the COVID-19 era: a retrospective quantitative analysis of antibiotic consumption and identification of antibiotic prescription drivers. Intern Emerg Med. 2022;17:141-51. [CrossRef]
22. Borulu B, Parlak E, Yılmaz S, Borulu F, Parlak M. The Causative Agents, Their Antimicrobial Susceptibilities and Their Effects on Mortality of Intensive Care Infections in Atatürk University Medical Faculty Research Hospital. MJIMA. 2021;10. [CrossRef]
23. Han J, Gatheral T, Williams C. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19. Clin Med (Lond). 2020;20:E47. [CrossRef]
24. Pink I, Raupach D, Fuge J, et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection. 2021;1:1. [CrossRef]
25. Van Berkel M, Kox M, Frenzel T, Pickkers P, Schouten J. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care. 2020;24. [CrossRef]
26. İEİS - İlaç Endüstrisi İşverenler Sendikası - Temel Göstergeler / Türkiye İlaç Pazarı :: - n.d. http://ieis.org.tr/ieis/tr/indicators/33/turkiye-ilac-pazari (accessed August 26, 2021). [CrossRef]